Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01085201 · ClinicalTrials.gov registry record · Phase 1

Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

A Phase 1 study of Sickle Cell Disease, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 1
Development phase
39
Enrollment target
7
Study locations

NCT01085201 is a Phase 1 study of Sickle Cell Disease that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 39 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01085201, a Phase 1 study of Sickle Cell Disease, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
39 participants
Enrollment target
7
Study locations

Study Summary

Sickle cell disease (SCD) is an inherited blood disorder that causes the red blood cells to change their shape from a round shape to a half-moon/crescent or sickled shape. People who have SCD have a different type of protein that carries oxygen in their blood (hemoglobin) then people without SCD. This different type of hemoglobin makes the red blood cells change into a crescent shape under certain conditions. Sickle-shaped cells are a problem because they often get stuck in blood vessels blocking the flow of blood, and cause inflammation and injury to the important areas in the body. Lexiscan is drug that may prevent this inflammation and injury caused by the sickle shaped cells. This drug is approved by the FDA to be used as a fast infusion during a heart stress test in people who are unable to exercise enough to put stress on their heart by making it beat faster. Lexiscan has never been studied in patients with SCD and has never been given as a long infusion.

Conditions Studied

Sickle Cell Disease

Interventions

  • DRUG Lexiscan

Study Locations (7)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Childrens Hospital Boston - Boston
  • Dana-Farber Cancer Institute - Boston

District of Columbia

  • Howard University Hospital - Washington D.C.

Maryland

  • Johns Hopkins University - Baltimore

Missouri

  • Washington University - St Louis

Wisconsin

  • Blood Center of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2010-04
Est. Completion 2013-03
Phase Phase 1

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01085201

The ClinicalTrials.gov registry entry for NCT01085201 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (87% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Lexiscan is the first listed.

NCT01085201 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT01085201 about?

NCT01085201 is a clinical study titled "Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease". Sickle cell disease (SCD) is an inherited blood disorder that causes the red blood cells to change their shape from a round shape to a half-moon/crescent or sickled shape. People who have SCD have a different type of protein that carries oxygen in their blood (hemoglobin) then people without SCD. Th...

What is the current status of trial NCT01085201?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2010-04. Estimated completion is 2013-03.

What conditions does trial NCT01085201 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT01085201?

The interventions under investigation include: Lexiscan (DRUG).

Who is sponsoring clinical trial NCT01085201?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01085201 being conducted?

This trial has 7 study locations across District of Columbia, Maryland, Massachusetts, Missouri, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.